Cat. # CHI-HF-210BTNL2
| Product Details | |
|---|---|
| Synonyms | Butyrophilin-like Protein 2; BTN7 |
| Product Type | Protein |
| Properties | |
| Source/Host | HEK 293 cells |
| Sequence | The extracellular domain of human BTNL2 (aa 24-455) is fused to the N-terminus of the Fc region of human IgG1. |
| Crossreactivity | Human |
| MW | ~74kDa (monomer) |
| Purity | ≥98% (SDS-PAGE) |
| Endotoxin Content | <0.06EU/μg protein (LAL test; Lonza). |
| Reconstitution | Reconstitute at 100μg/ml in sterile PBS. |
| Formulation | Lyophilized from 0.2μm-filtered solution in PBS. |
| Other Product Data | NCBI reference NP_062548.1: BTNL2 (human) |
| Declaration | Manufactured by Chimerigen. |
| Shipping and Handling | |
| Shipping | BLUE ICE |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Handling Advice | Avoid freeze/thaw cycles. |
| Use/Stability | Stable for at least 1 year after receipt when stored at -20°C. Working aliquots are stable for up to 3 months when stored at -20°C. |
BTNL2 (human):Fc (human) (rec.)
Butyrophilin-like 2 (BTNL2) is a butyrophilin family member with homology to the B7 costimulatory molecules, polymorphisms of which have been recently associated through genetic analysis; to sporadic inclusion body myositis and sarcoidosis. BTNL2 mRNA is highly expressed in lymphoid tissues as well as in intestine. BTNL2-Ig fusion protein was shown to recognize a putative receptor whose expression on B and T cells was significantly enhanced after activation. It inhibited T cell proliferation and TCR activation of NFAT, NF-κB and AP-1 signaling pathways. BTNL2 is the first member of the butyrophilin family that regulates T cell activation, which has implications in immune diseases and immunotherapy.